Fig. 1 · Structure

Documents & Downloads

AG-1478 (Tyrphostin AG-1478)

Cat. No. A11022 CAS 153436-53-4

EGFR Inhibitor

AG-1478 (Tyrphostin AG-1478) is an inhibitor of EGFR kinase with an IC50 value of 3 nM.

In Stock

Publications for AG-1478

2 publications citing this product

  1. Khattab M, .et al. , J Phys Chem B, 2018, May 3;122(17):4667-4679 PMID: 29629773
  2. Muhammad Khattab, .et al. , Sci Rep, 2017, 7: 16271 PMID: 29176733

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AG1478 inhibits EGFR signaling in experimental systems. In cultured mouse preovulatory follicles, it suppressed LH-induced EGFR phosphorylation while only partially suppressing downstream MAPK1/3 phosphorylation. [1]

Cell-free absorption spectroscopy gave a fitted AG1478 pKa of 5.58 ± 0.01 in aqueous buffer containing 0.5% DMSO. This solution measurement does not establish cellular potency. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
EGFR (Cell-free assay) 3 nM
HER2 (Cell-free assay) >100 μM
PDGFR (Cell-free assay) >100 μM

Cellular Effect

Cell Line Activity Value Description Reference
A-431 IC50 0.31 nM Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles [PMID: 8568816]

AG-1478 (Tyrphostin AG-1478) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of AG-1478 (Tyrphostin AG-1478) from 4 published references. In vivo models include male and female B6-ApcMin/+ and AB6F1-ApcMin/+ mice.

AG-1478 (Tyrphostin AG-1478) In Vitro Studies

At 0.5 µM, with 30 minutes of pretreatment followed by 30 minutes of LH stimulation, AG1478 reduced EGFR phosphorylation and produced approximately 60% inhibition of MAPK1/3 phosphorylation in cultured mouse follicles. The remaining MAPK response indicates additional signaling inputs. [1]

Cell-free solution ionization measured by absorption spectroscopy

Biochemical assay · AG1478 in aqueous buffers containing 0.5% DMSO [2]

Solution spectroscopy identified a pH-dependent transition; this is a physicochemical assay, not an EGFR enzyme inhibition assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Acid–base transition fitted to optical-density data over pH 1–12pKa 5.58 ± 0.01[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
10 min equilibration
Method
UV-Vis spectroscopy; buffer/DMSO reference cuvette
Vehicle
0.5% DMSO (v/v) in aqueous buffer
Reported limits
The meaning of ± on the fitted pKa is not explicitly identified in the read Results; five spectral scans are reported for wavelength maxima, not five biological replicates.
Methods and source locations

Compound reported in the paper: AG1478 (Tyrphostin AG-1478); Compound label in the paper: AG1478

Reported AG1478 material only; no Adooq lot equivalence, salt conversion or clinical extrapolation.

Results: Absorption spectroscopy study; Figure 4A–B and caption; Materials and Methods: Materials, UV-Vis spectroscopy

Acid–base transition fitted to optical-density data over pH 1–12: Boltzmann fit; Figure 4A. Points at pH 13 and 13.3 excluded from fit (caption). — Results: Absorption spectroscopy study; Figure 4A–B and caption; Materials and Methods: Materials, UV-Vis spectroscopy

EGFR and MAPK signaling in cultured mouse preovulatory follicles

Cell-based study · Preovulatory follicles isolated from PMSG-primed immature female C57BL/6 mice [1]

AG1478 suppressed LH-induced EGFR phosphorylation and partially suppressed MAPK1/3 phosphorylation relative to LH-stimulated vehicle controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LH-induced phosphorylated EGFR/total EGFR normalized to controlDirection; significance Reduced; P < 0.05; mean ± SEM, four separate experiments[1]
LH-induced phosphorylated MAPK1/3/total MAPK normalized to controlInhibition Approximately 60% (reported in Results); P < 0.05; mean ± SEM, four separate experiments[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 µM
Exposure duration
30 min pretreatment, followed by 30 min rLH stimulation
Method
Ex vivo follicle culture; immunoprecipitation and Western blotting
Vehicle
DMSO
Co-treatment
rLH (5 IU) as stimulus; AG1478 and GM6001 were separate experimental treatments
Reported limits
DMSO percentage and AG1478 lot/form specification are not reported in the selected methods.
Methods and source locations

Compound reported in the paper: AG1478 (Tyrphostin AG-1478); Compound label in the paper: AG1478

Reported AG1478 material only; no Adooq lot equivalence, salt conversion or clinical extrapolation.

Results: LH-Induced MAPK1/3 Activation Is Dependent in Part on EGFR Activity; Figure 4A,B,E and caption; MATERIALS AND METHODS: Materials, POF Culture, Immunoprecipitation and Immunoblotting, Statistics

LH-induced phosphorylated EGFR/total EGFR normalized to control: Figure 4A,E; anti-pY1068-EGFR immunoblot after EGFR immunoprecipitation; total EGFR control. — Results: LH-Induced MAPK1/3 Activation Is Dependent in Part on EGFR Activity; Figure 4A,B,E and caption; MATERIALS AND METHODS: Materials, POF Culture, Immunoprecipitation and Immunoblotting, Statistics

LH-induced phosphorylated MAPK1/3/total MAPK normalized to control: Figure 4B,E; phospho/total MAPK immunoblots; untreated, inhibitor-only, LH-only and LH-plus-inhibitor controls. — Results: LH-Induced MAPK1/3 Activation Is Dependent in Part on EGFR Activity; Figure 4A,B,E and caption; MATERIALS AND METHODS: Materials, POF Culture, Immunoprecipitation and Immunoblotting, Statistics

AG-1478 (Tyrphostin AG-1478) In Vivo Studies

Dietary AG1478 reduced intestinal tumor endpoints in ApcMin/+ mice, with responses depending on genetic background and diet. In the B6 background, the tumor-number response on Western diet did not remain significant after multiple-comparison correction; the standard-diet tumor-size comparison was also nonsignificant. [3]

Chronic dietary AG1478 was associated with reduced reported left ventricular fractional shortening in female C57BL/6J mice, whereas male echocardiographic endpoints were not significantly altered. The female pairwise significance annotation coexisted with a nonsignificant omnibus fractional-shortening test; the reported AG1478 TUNEL comparison was P < 0.06. [4]

Sex-dependent cardiac findings after chronic dietary AG1478

Animal study · Wild-type C57BL/6J mice, male and female, 6–8 weeks old at allocation [4]

Reported fractional shortening was lower in treated females; male echocardiographic endpoints were not significantly altered. Histological findings support a model-specific adverse-effect signal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Female left ventricular fractional shortening%FS; mean ± SEM Control 42.42 ± 5.53 (n=6); AG-1478 29.34 ± 2.56 (n=5); ¥ denotes P < 0.01 versus control[4]
Male left ventricular fractional shortening%FS; mean ± SEM Control 35.17 ± 3.94 (n=4); AG-1478 35.07 ± 2.00 (n=5); ANOVA ns[4]
Female cardiac TUNEL-positive cells compared with controlReported pairwise P P < 0.06 (AG-1478 versus control)[4]

Conditions shared by the study groups

Route
Oral, diet
Frequency
Ad libitum
Treatment course
90 days
Vehicle
AIN-93G chow
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Female AG1478 versus control chow
144 mg/kg food (authors’ equivalent: 19.2 mg/kg body weight/day)
Same base chow without inhibitorLower reported %FS with pairwise P < 0.01; omnibus %FS ANOVA ns. Figure 3B shows fibrosis; TUNEL comparison P < 0.06 is not conventionally significant.[4]
Male AG1478 versus control chow
144 mg/kg food (authors’ equivalent: 19.2 mg/kg body weight/day)
Same base chow without inhibitorNo significant changes in the tabulated echocardiographic endpoints; no general claim of absence of all molecular effects.[4]
Female AG1478 versus control chow
Model: C57BL/6J female; TTE control n=6, AG1478 n=5
Reported limits: Endpoint n is not initial enrollment n; individual intake not provided.
Male AG1478 versus control chow
Model: C57BL/6J male; TTE control n=4, AG1478 n=5
Reported limits: Endpoint n is not initial enrollment n; individual intake not provided.
Methods and source locations

Compound reported in the paper: AG1478 (Tyrphostin AG-1478); Compound label in the paper: AG1478

Reported AG1478 material only; no Adooq lot equivalence, salt conversion or clinical extrapolation.

Materials and methods: Animals and pharmacologic treatment, Echocardiography, Statistical analysis; Table 3 and footnotes; Results: EGFR inhibition results in altered cardiovascular function; Figure 3B–E

Female left ventricular fractional shortening: Reported TTE endpoint, Table 3. Its female omnibus ANOVA entry for %FS is ns; the pairwise annotation must not be read as an omnibus result. — Materials and methods: Animals and pharmacologic treatment, Echocardiography, Statistical analysis; Table 3 and footnotes; Results: EGFR inhibition results in altered cardiovascular function; Figure 3B–E

Male left ventricular fractional shortening: Table 3; TTE. No significant male changes in the tabulated echocardiographic endpoints. — Materials and methods: Animals and pharmacologic treatment, Echocardiography, Statistical analysis; Table 3 and footnotes; Results: EGFR inhibition results in altered cardiovascular function; Figure 3B–E

Female cardiac TUNEL-positive cells compared with control: Results accompanying Figure 3D; Fisher’s PSLD as printed. This does not meet the paper’s stated P < 0.05 threshold. — Materials and methods: Animals and pharmacologic treatment, Echocardiography, Statistical analysis; Table 3 and footnotes; Results: EGFR inhibition results in altered cardiovascular function; Figure 3B–E

Female AG1478 versus control chow · Materials and methods: Animals and pharmacologic treatment, Echocardiography, Statistical analysis; Table 3 and footnotes; Results: EGFR inhibition results in altered cardiovascular function; Figure 3B–E

Male AG1478 versus control chow · Materials and methods: Animals and pharmacologic treatment, Echocardiography, Statistical analysis; Table 3 and footnotes; Results: EGFR inhibition results in altered cardiovascular function; Figure 3B–E

Diet and genetic background modify AG1478-associated intestinal tumor responses

Animal study · Male and female B6-ApcMin/+ and AB6F1-ApcMin/+ mice [3]

In the ApcMin/+ model, mixed models associated AG1478 with fewer small-intestinal tumors and smaller small-intestinal tumors; corrected pairwise responses varied with background and diet.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AG1478 association with small-intestinal tumor number and size, controlling for strainLinear mixed model significance Tumor number P = 0.003; tumor size P < 0.001[3]
Pairwise tumor-number/size responses by background and dietMultiple-comparison-corrected summary B6: standard diet, number decreased, size no significant decrease; Western diet, number trend only, size decreased. F1: both endpoints decreased on both diets.[3]

Conditions shared by the study groups

Route
Oral, diet
Frequency
Ad libitum
Treatment course
9 weeks from weaning
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
B6 Standard diet ± AG1478
144 mg/kg chow
Matched genotype/diet without AG1478Table 2: tumor number decreased; no significant size decrease.[3]
B6 Western diet ± AG1478
144 mg/kg chow
Matched genotype/diet without AG1478Table 2: tumor-number trend failed correction; size decreased.[3]
AB6F1 Standard diet ± AG1478
144 mg/kg chow
Matched genotype/diet without AG1478Table 2: tumor number and size decreased.[3]
AB6F1 Western diet ± AG1478
144 mg/kg chow
Matched genotype/diet without AG1478Table 2: tumor number and size decreased.[3]
B6 Standard diet ± AG1478
Model: B6-ApcMin/+ both sexes; control n=11 (6 females); AG1478 n=11 (6 females)
Vehicle: AIN-93G
Reported limits: Group counts from Figure 1; individual intake not given.
B6 Western diet ± AG1478
Model: B6-ApcMin/+ both sexes; control n=10 (5 females); AG1478 n=11 (6 females)
Vehicle: D12079B
Reported limits: Group counts from Figure 1; individual intake not given.
AB6F1 Standard diet ± AG1478
Model: AB6F1-ApcMin/+ both sexes; control n=29 (14 females); AG1478 n=26 (14 females)
Vehicle: AIN-93G
Reported limits: Group counts from Figure 1; individual intake not given.
AB6F1 Western diet ± AG1478
Model: AB6F1-ApcMin/+ both sexes; control n=29 (15 females); AG1478 n=28 (14 females)
Vehicle: D12079B
Reported limits: Group counts from Figure 1; individual intake not given.
Methods and source locations

Compound reported in the paper: AG1478 (Tyrphostin AG-1478); Compound label in the paper: AG1478

Reported AG1478 material only; no Adooq lot equivalence, salt conversion or clinical extrapolation.

Experimental Design (ApcMin/+ cohort); Figure 1 ApcMin/+ rows; Figures 2A and 3A with captions; Table 2 and Statistical Analysis; Results: Efficacy of EGFR Inhibition on Tumor Growth is Variable Across Diet, Model, Sex and Strain

AG1478 association with small-intestinal tumor number and size, controlling for strain: Figures 2A,3A and Results; strain random effect, diet/treatment/sex fixed effects. These are associations across the design, not universal pairwise efficacy. — Experimental Design (ApcMin/+ cohort); Figure 1 ApcMin/+ rows; Figures 2A and 3A with captions; Table 2 and Statistical Analysis; Results: Efficacy of EGFR Inhibition on Tumor Growth is Variable Across Diet, Model, Sex and Strain

Pairwise tumor-number/size responses by background and diet: Table 2: decrease means corrected P < 0.05; trend means uncorrected P < 0.05 but corrected P > 0.05. Sex not included in this summary. — Experimental Design (ApcMin/+ cohort); Figure 1 ApcMin/+ rows; Figures 2A and 3A with captions; Table 2 and Statistical Analysis; Results: Efficacy of EGFR Inhibition on Tumor Growth is Variable Across Diet, Model, Sex and Strain

B6 Standard diet ± AG1478 · Experimental Design (ApcMin/+ cohort); Figure 1 ApcMin/+ rows; Figures 2A and 3A with captions; Table 2 and Statistical Analysis; Results: Efficacy of EGFR Inhibition on Tumor Growth is Variable Across Diet, Model, Sex and Strain

B6 Western diet ± AG1478 · Experimental Design (ApcMin/+ cohort); Figure 1 ApcMin/+ rows; Figures 2A and 3A with captions; Table 2 and Statistical Analysis; Results: Efficacy of EGFR Inhibition on Tumor Growth is Variable Across Diet, Model, Sex and Strain

AB6F1 Standard diet ± AG1478 · Experimental Design (ApcMin/+ cohort); Figure 1 ApcMin/+ rows; Figures 2A and 3A with captions; Table 2 and Statistical Analysis; Results: Efficacy of EGFR Inhibition on Tumor Growth is Variable Across Diet, Model, Sex and Strain

AB6F1 Western diet ± AG1478 · Experimental Design (ApcMin/+ cohort); Figure 1 ApcMin/+ rows; Figures 2A and 3A with captions; Table 2 and Statistical Analysis; Results: Efficacy of EGFR Inhibition on Tumor Growth is Variable Across Diet, Model, Sex and Strain

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 153436-53-4
Applications EGFR Inhibitor
Formula C16H14ClN3O2
Molecular Weight 315.8
Synonyms Tyrphostin AG-1478
SMILES
COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 25 mg/mL (79.17 mM)
Water Insoluble
Ethanol 13 mg/mL (41.17 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
15% Captisol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

AG-1478 (Tyrphostin AG-1478) Research References

  1. [1] Sara Panigone, Minnie Hsieh, Maoyong Fu, et al. Luteinizing Hormone Signaling in Preovulatory Follicles Involves Early Activation of the Epidermal Growth Factor Receptor Pathway Molecular Endocrinology (2008). PMID: 18187604 DOI: 10.1210/me.2007-0246 Source material
  2. [2] Muhammad Khattab, Feng Wang, Andrew H A Clayton. A pH-induced conformational switch in a tyrosine kinase inhibitor identified by electronic spectroscopy and quantum chemical calculations Scientific Reports (2017). PMID: 29176733 DOI: 10.1038/s41598-017-16583-z Source material
  3. [3] Erica S Rinella, David W Threadgill. Efficacy of EGFR Inhibition Is Modulated by Model, Sex, Genetic Background and Diet: Implications for Preclinical Cancer Prevention and Therapy Trials PLoS ONE (2012). PMID: 22761823 DOI: 10.1371/journal.pone.0039552 Source material
  4. [4] Cordelia J Barrick, Ming Yu, Hann-Hsiang Chao, et al. Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice Toxicology and applied pharmacology (2008). PMID: 18313710 DOI: 10.1016/j.taap.2007.12.012 Source material

Publications

2 publications citing this product

  1. Khattab M, .et al. , J Phys Chem B, 2018, May 3;122(17):4667-4679 PMID: 29629773
  2. Muhammad Khattab, .et al. , Sci Rep, 2017, 7: 16271 PMID: 29176733

Added to your cart

View Cart Checkout
Loading...